Navigation Links
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Date:2/25/2008

PEC) scores at 20 minutes post- dose, as compared to placebo. The effectiveness of the 10 mg dose was sustained throughout the 24-hour study period, as compared to placebo.

About Alexza Pharmaceuticals, Inc.

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.

Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. AZ-003 (Staccato fentanyl), which is partnered with Endo Pharmaceuticals in North America, for the treatment of breakthrough pain and AZ-007 (Staccato zaleplon) for the treatment of insomnia are in Phase 1 testing. More information, including this and past press releases from Alexza is available online at http://www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of AZ-004, the development of the Company's product candidates, projected clinical trial enrollment and data repor
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
2. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
3. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
4. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
5. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
6. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... ADELAIDE, Australia , Feb. 27, 2015 ... data from the DisrupTOR-1 trial of BNC105 in patients ... Symposium in Orlando, Florida . The ... of the City of Hope Comprehensive Cancer Center ... presentation. The new data identifies Ferritin ...
(Date:2/27/2015)... Brighton, Illinois (PRWEB) February 27, 2015 ... Matt Sims, General Manager of State Line Farms, received ... Award recognizes a producer, under the age of 35, ... , "It is an honor to win the Tomorrow's ... to discovering who won the Top Producer Award and ...
(Date:2/27/2015)... -- Steep Hill, the industry leader in cannabis testing and ... a full service medical cannabis quality assurance laboratory in ... scientific tools and methodology to the state, for regulatory ... the only laboratory licensed by the New Mexico Department ... order to meet the recently adopted regulatory requirements pertaining ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
... March 31 DOR BioPharma, Inc. (OTC Bulletin Board: ... today announced its financial results for 2008. DOR,s revenues ... million in 2007. The increase was due primarily ... the resulting achievement of certain research and development milestones ...
... IDM Pharma, Inc. (Nasdaq: IDMI ) today ... ended December 31, 2008. Financial information presented represents the ... Pharma S.A.Total revenues in the quarter ended December 31, 2008 ... $0.07 per share for the quarter. Total revenues for ...
... leader of cell line manufacturing, Selexis is now ... recombinant protein drugs with added characterization servicesGENEVA, March ... offering technologies and services for the rapid development ... an expanded offering focusing on the biosimilar market ...
Cached Biology Technology:DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments 5IDM Pharma Reports 2008 Financial Results 2IDM Pharma Reports 2008 Financial Results 3IDM Pharma Reports 2008 Financial Results 4IDM Pharma Reports 2008 Financial Results 5IDM Pharma Reports 2008 Financial Results 6IDM Pharma Reports 2008 Financial Results 7IDM Pharma Reports 2008 Financial Results 8Selexis Launches Biosimilar Cell Line Development Program 2
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
Breaking Biology News(10 mins):BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... Want to slow the signs of aging and live ... calories could be a promising strategy. Calorie restriction ... rats and mice. While scientists do not know how calorie ... is that it slows aging by decreasing a thyroid hormone, ...
... a bold commitment from Germany, leaders of the world,s ... Summit in Japan to take immediate and substantive action ... pledge of 500 million Euros over four years to ... forest protection, starts to address a major source of ...
... COLLEGE STATION, July 2, 2008 -- Two Texas A&M ... help scientists more accurately study complex units of clustered ... scientists to analyze many bacterial genomes at once, is ... experimentally validated data instead of from statistical predictions, they ...
Cached Biology News:Looking for the Founatain of Youth? Cut your calories, research suggests 2G8 summit: Opportunity for immediate action on climate change 2G8 summit: Opportunity for immediate action on climate change 3Texas A&M researchers develop tool to study complex clusters of genes 2Texas A&M researchers develop tool to study complex clusters of genes 3
... have moderate chemiluminescence efficiencies and the chemistry ... have the added benefit that they require ... the background signal. This benefit has been ... immunoassay applications. These compounds can also be ...
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
... version of Freezerworks Unlimited includes 2 clients and ... facilitates the sharing of freezers by multiple groups ... Network Client/Server version ... in monitor with 256 colors; OS 8.6 & ...
Biology Products: